Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer

This study has been completed.
Information provided by (Responsible Party):
FKD Therapies Oy Identifier:
First received: September 6, 2012
Last updated: February 2, 2016
Last verified: March 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2016
  Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)